SynthesisPloS one2026
Prevalence of hyperuricemia in preeclampsia: A systematic review and meta-analysis of studies from low - and middle - income countries.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia is a recognized biochemical finding in preeclampsia (PE), but the reported frequency varies across low- and middle-income countries (LMICs). A pooled estimate from LMIC settings may help clarify the extent of this finding in hospital-based populations.
objectiveTo estimate the pooled prevalence of hyperuricemia among women with preeclampsia in hospital-based studies from LMICs.
methodsA systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420251107624). PubMed, Scopus, Web of Science, and Lens.org were searched for observational studies published from 2010 to 2025 reporting hyperuricemia among women with preeclampsia in LMIC hospital settings. Prevalence estimates were pooled using a random-effects model with logit transformation. Heterogeneity was assessed using Cochran's Q, Tau², and I². Sensitivity analyses included subgrouping by hyperuricemia threshold and leave-one-out analysis.
resultsEleven studies involving 1,099 women with preeclampsia from seven LMICs were included. The pooled prevalence of hyperuricemia was 53.47% (95% CI: 45.17% to 61.58%), with low-to-moderate heterogeneity (I² = 27.47%, p = 0.204). Included studies used different diagnostic thresholds for hyperuricemia, ranging from 5.0 to 7.0 mg/dL. All studies were hospital-based, and reporting of gestational age at the time of uric acid measurement was inconsistent.
conclusionsHyperuricemia was common among women with preeclampsia in hospital-based LMIC studies. These findings describe prevalence only and should not be interpreted as evidence of diagnostic accuracy, prognostic performance, or clinical utility. Future studies should standardize diagnostic thresholds and report gestational timing of uric acid measurement more consistently.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.